GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Processa Pharmaceuticals Inc (NAS:PCSA) » Definitions » EBITDA per Share

PCSA (Processa Pharmaceuticals) EBITDA per Share : $-3.16 (TTM As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Processa Pharmaceuticals EBITDA per Share?

Processa Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2025 was $-0.30. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.16.

During the past 3 years, the average EBITDA per Share Growth Rate was 34.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 23.00% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Processa Pharmaceuticals's EBITDA per Share or its related term are showing as below:

PCSA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.5   Med: 29.8   Max: 74.6
Current: 34.6

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Processa Pharmaceuticals was 74.60% per year. The lowest was -70.50% per year. And the median was 29.80% per year.

PCSA's 3-Year EBITDA Growth Rate is ranked better than
75.18% of 1233 companies
in the Biotechnology industry
Industry Median: 10.7 vs PCSA: 34.60

Processa Pharmaceuticals's EBITDA for the three months ended in Mar. 2025 was $-2.85 Mil.

During the past 3 years, the average EBITDA Growth Rate was -3.80% per year. During the past 5 years, the average EBITDA Growth Rate was -21.00% per year. During the past 10 years, the average EBITDA Growth Rate was -36.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Processa Pharmaceuticals was 66.90% per year. The lowest was -223.70% per year. And the median was -10.35% per year.


Processa Pharmaceuticals EBITDA per Share Historical Data

The historical data trend for Processa Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Processa Pharmaceuticals EBITDA per Share Chart

Processa Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -38.21 -14.07 -24.19 -8.73 -3.94

Processa Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.14 -1.03 -1.05 -0.78 -0.30

Processa Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Processa Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA per Share(A: Dec. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=-12.05/3.060
=-3.94

Processa Pharmaceuticals's EBITDA per Share for the quarter that ended in Mar. 2025 is calculated as

EBITDA per Share(Q: Mar. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-2.847/9.527
=-0.30

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Processa Pharmaceuticals  (NAS:PCSA) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Processa Pharmaceuticals EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Processa Pharmaceuticals's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Processa Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7380 Coca Cola Drive, Suite 106, Hanover, MD, USA, 21076
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Executives
George K Ng officer: Chief Executive Officer C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121
Justin W Yorke director C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101
David Young director, 10 percent owner, officer: President & CEO 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045
Patrick Lin officer: Chief Business - Strategy Off 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Wendy Guy officer: Chief Administrative Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James H Stanker officer: Chief Financial Officer 9008 SHADYBROOK DRIVE, FREDERICK MD 21701
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Virgil Thompson director 319 SOUTH NARDO, SOIANA BEACH CA 92075
Geraldine Pannu director 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
Robert Michael Floyd officer: Chief Operating Officer C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sian Bigora officer: Chief Development Officer 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076